Success Metrics

Clinical Success Rate
82.3%

Based on 51 completed trials

Completion Rate
82%(51/62)
Active Trials
1(1%)
Results Posted
43%(22 trials)
Terminated
11(15%)

Phase Distribution

Ph phase_4
22
29%
Ph not_applicable
6
8%
Ph phase_3
14
19%
Ph phase_1
12
16%
Ph phase_2
16
21%

Phase Distribution

12

Early Stage

16

Mid Stage

36

Late Stage

Phase Distribution70 total trials
Phase 1Safety & dosage
12(17.1%)
Phase 2Efficacy & side effects
16(22.9%)
Phase 3Large-scale testing
14(20.0%)
Phase 4Post-market surveillance
22(31.4%)
N/ANon-phased studies
6(8.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

78.5%

51 of 65 finished

Non-Completion Rate

21.5%

14 ended early

Currently Active

1

trials recruiting

Total Trials

75

all time

Status Distribution
Active(1)
Completed(51)
Terminated(14)
Other(9)

Detailed Status

Completed51
Terminated11
unknown9
Withdrawn3
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
75
Active
1
Success Rate
82.3%
Most Advanced
Phase 4

Trials by Phase

Phase 112 (17.1%)
Phase 216 (22.9%)
Phase 314 (20.0%)
Phase 422 (31.4%)
N/A6 (8.6%)

Trials by Status

recruiting11%
unknown912%
withdrawn34%
completed5168%
terminated1115%

Recent Activity

Clinical Trials (75)

Showing 20 of 75 trialsScroll for more
NCT02738008Phase 2

Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection

Terminated
NCT02604199Phase 2

A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection

Terminated
NCT02604212Phase 2

A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection

Terminated
NCT02797522Phase 1

A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)

Terminated
NCT00042289

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Completed
NCT02452528Phase 2

Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus

Terminated
NCT07084948Phase 4

Using Flavonoids to Kill Hepatitis B Virus

Completed
NCT06295328Phase 1

From Fungus to Virus, Investigating the Safety and Efficacy of Terbinafine in Chronic Hepatitis B Patients

Recruiting
NCT03218085

Role of Exogenous and Endogenous Sex Hormones on Tenofovir and Emtricitabine Disposition in Female Genital Tract

Completed
NCT02650271Phase 3

Adjuvant Entecavir or Tenofovir for Postoperative HBV-HCC

Completed
NCT00350272Phase 2

Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants

Completed
NCT02475915Phase 1

Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection

Completed
NCT01369212Phase 3

Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B

Completed
NCT03986970Phase 2

The CHAPS Trial: Combined HIV Adolescent PrEP and Prevention

Completed
NCT03782142

Effect on HIV Medications on EPC Cells

Completed
NCT04431375Not Applicable

Efficacy of Addition of Fecal Microbiota Transplant (FMT) and Plasma Exchange to Tenofovir in Comparison to Monotherapy With Tenofovir in ACLF-HBV

Unknown
NCT00028132Phase 1

Safety and Acceptability of the Anti-Microbe Vaginal Gel, PMPA Gel

Completed
NCT02369965Phase 3

Test Albuvirtide in Experienced Patients

Completed
NCT00214890Phase 2

Viral Dynamics and Pharmacokinetics of Abacavir and Tenofovir

Completed
NCT03759782Phase 3

Ribavirin to Enhance Hepatitis B Virus Nucleotide Analog Antiviral Activity

Unknown

Drug Details

Intervention Type
DRUG
Total Trials
75